Make your one-time, tribute, or recurring online gift to support brain tumour patient programs and research today: Donate
Dr. Sabine Mai
Manitoba Institute of Cell Biology, Winnipeg, MB
The proposed study focuses on ependymoma, a childhood brain tumour. At diagnosis, it is not possible to know which child will respond to treatment and which child will recur, i.e. if prognosis is favourable or non-favourable. We have developed quantitative tools that may allow for the distinction of good and poor responders at diagnosis.
These tools involve three-dimensional (3D) imaging of telomeres. Telomeres are the ends of chromosomes; they protect the chromosomes from damage and prevent recombination and fusion with other chromosomes (Mai, 2010). Telomere dysfunction therefore is associated with genomic instability and found in many cancers (Mai and Garini, 2006; Mai, 2010).
The data obtained in this study are quantitatively measured, and the output is expected to be a 3D nuclear telomeric profile of each child’s tumour, indicative of favourable or non-favourable disease and will, in the near future, enable for the first time a choice for specific treatments for each child’s ependymoma.
When you look back at Brain Tumour Foundation of Canada’s history, it’s clear that at the heart of the organization are the patients, survivors and loved ones who care for those diagnosed. It’s this amazing community of supporters – even amidst what is often a life-changing journey – who volunteer their time, host fundraising events and donate in memory of those they’ve lost to the disease.Learn more
Read why Katherine is now "filled with gratitude" despite a diagnosis of Anaplastic-Ependymoma, stage 3 brain cancer, at the age of...Learn more
When John Hatcher laces up his running shoes on Saturday, October 2, 2016 he joins over a dozen of his family members and friends for...Learn more